{"pmid":32346394,"pmcid":"PMC7176064","title":"Additional challenges faced by cancer patients in Gaza due to COVID-19.","text":["Additional challenges faced by cancer patients in Gaza due to COVID-19.","Cancer patients in conflict settings experience significant barriers in accessing chemotherapy and radiotherapy as well as palliative care and psychosocial support. Now they face an additional possible risk of infection by SARS-CoV-2 novel coronavirus and the indirect impact of the COVID-19 pandemic on movement restrictions and their access to care. In this commentary, we highlight that despite the low COVID-19 burden in conflict settings like Gaza, COVID-19 could lead to further inequity in cancer care and poorer outcomes for Palestinians with cancer. This is due to the pre-existing shortage in cancer resources as well as the lack of context-specific guidelines to prepare for COVID-19 in war-torn settings.","Ecancermedicalscience","AlWaheidi, Shaymaa","Sullivan, Richard","Davies, Elizabeth A","32346394"],"abstract":["Cancer patients in conflict settings experience significant barriers in accessing chemotherapy and radiotherapy as well as palliative care and psychosocial support. Now they face an additional possible risk of infection by SARS-CoV-2 novel coronavirus and the indirect impact of the COVID-19 pandemic on movement restrictions and their access to care. In this commentary, we highlight that despite the low COVID-19 burden in conflict settings like Gaza, COVID-19 could lead to further inequity in cancer care and poorer outcomes for Palestinians with cancer. This is due to the pre-existing shortage in cancer resources as well as the lack of context-specific guidelines to prepare for COVID-19 in war-torn settings."],"journal":"Ecancermedicalscience","authors":["AlWaheidi, Shaymaa","Sullivan, Richard","Davies, Elizabeth A"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32346394","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3332/ecancer.2020.ed100","keywords":["covid-19","gaza","breast cancer"],"locations":["Gaza","Palestinians","Gaza"],"countries":["Palestine, State of"],"countries_codes":["PSE|Palestine, State of"],"topics":["Prevention"],"weight":1,"_version_":1665441658239451136,"score":8.599203,"similar":[{"pmid":32292842,"pmcid":"PMC7118660","title":"Breast radiotherapy under COVID-19 pandemic resource constraints -- approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States.","text":["Breast radiotherapy under COVID-19 pandemic resource constraints -- approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States.","Introduction: Breast radiotherapy accounts for a significant proportion of patient volume in contemporary radiation oncology practice. In the setting of anticipated resource constraints and widespread community infection with SARS-CoV-2 during the COVID-19 pandemic, measures for balancing both infectious and oncologic risk among patients and providers must be carefully considered. Here, we present evidence-based guidelines for omitting or abbreviating breast cancer radiotherapy, where appropriate, in an effort to mitigate risk to patients and optimize resource utilization. Methods: Multidisciplinary breast cancer experts at a high-volume comprehensive cancer center convened contingency planning meetings over the early days of the COVID-19 pandemic to review the relevant literature and establish recommendations for the application of hypofractionated and abbreviated breast radiation regimens. Results: Substantial evidence exists to support omitting radiation among certain favorable risk subgroups of breast cancer patients and for abbreviating or accelerating regimens among others. For those who require either whole-breast or post-mastectomy radiation, with or without coverage of the regional lymph nodes, a growing body of literature supports various hypofractionated approaches that appear safe and effective. Conclusion: In the setting of a public health emergency with the potential to strain critical healthcare resources and place patients at infection risk, the parsimonious application of breast radiotherapy may alleviate a significant clinical burden without compromising long term oncologic outcomes. The judicious and personalized use of immature study data may be warranted in the setting of a competing mortality risk from this widespread pandemic.","Adv Radiat Oncol","Braunstein, Lior Z","Gillespie, Erin F","Hong, Linda","Xu, Amy","Bakhoum, Samuel F","Cuaron, John","Mueller, Boris","McCormick, Beryl","Cahlon, Oren","Powell, Simon","Khan, Atif J","32292842"],"abstract":["Introduction: Breast radiotherapy accounts for a significant proportion of patient volume in contemporary radiation oncology practice. In the setting of anticipated resource constraints and widespread community infection with SARS-CoV-2 during the COVID-19 pandemic, measures for balancing both infectious and oncologic risk among patients and providers must be carefully considered. Here, we present evidence-based guidelines for omitting or abbreviating breast cancer radiotherapy, where appropriate, in an effort to mitigate risk to patients and optimize resource utilization. Methods: Multidisciplinary breast cancer experts at a high-volume comprehensive cancer center convened contingency planning meetings over the early days of the COVID-19 pandemic to review the relevant literature and establish recommendations for the application of hypofractionated and abbreviated breast radiation regimens. Results: Substantial evidence exists to support omitting radiation among certain favorable risk subgroups of breast cancer patients and for abbreviating or accelerating regimens among others. For those who require either whole-breast or post-mastectomy radiation, with or without coverage of the regional lymph nodes, a growing body of literature supports various hypofractionated approaches that appear safe and effective. Conclusion: In the setting of a public health emergency with the potential to strain critical healthcare resources and place patients at infection risk, the parsimonious application of breast radiotherapy may alleviate a significant clinical burden without compromising long term oncologic outcomes. The judicious and personalized use of immature study data may be warranted in the setting of a competing mortality risk from this widespread pandemic."],"journal":"Adv Radiat Oncol","authors":["Braunstein, Lior Z","Gillespie, Erin F","Hong, Linda","Xu, Amy","Bakhoum, Samuel F","Cuaron, John","Mueller, Boris","McCormick, Beryl","Cahlon, Oren","Powell, Simon","Khan, Atif J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292842","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.adro.2020.03.013","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1665420446782193665,"score":254.45596},{"pmid":32322758,"pmcid":"PMC7175910","title":"Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center.","text":["Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center.","The COVID-19 pandemic will consume significant health care resources. Given concerns for rapidly rising infection rates in the US, impending staffing shortages, and potential for resource re-allocation, we rapidly re-evaluated our rectal cancer practice polices during this public health emergency. Previous to the pandemic we commonly utilized total neoadjuvant therapy (TNT) with a strong preference for long course chemoradiation (LCCRT). In the setting of the ongoing pandemic we now mandate short course radiation therapy (SCRT). Despite multiple randomized trials demonstrating no difference in locoregional recurrence, distant recurrence, or overall survival between SCRT and LRCCT, adaptation of SCRT in the United States has been low given concerns for less tumor downstaging and increased toxicity. In the setting of the ongoing and likely prolonged COVID-19 pandemic, we feel that these concerns must be re-evaluated, as SCRT presents a well-validated alternative that will allow us to meet the needs of a greater number of potentially curable patients, at a time when our resources are severely and acutely constrained.","Adv Radiat Oncol","Romesser, Paul B","Wu, Abraham J","Cercek, Andrea","Smith, J Joshua","Weiser, Martin","Saltz, Leonard","Garcia-Aguilar, Julio","Crane, Christopher H","32322758"],"abstract":["The COVID-19 pandemic will consume significant health care resources. Given concerns for rapidly rising infection rates in the US, impending staffing shortages, and potential for resource re-allocation, we rapidly re-evaluated our rectal cancer practice polices during this public health emergency. Previous to the pandemic we commonly utilized total neoadjuvant therapy (TNT) with a strong preference for long course chemoradiation (LCCRT). In the setting of the ongoing pandemic we now mandate short course radiation therapy (SCRT). Despite multiple randomized trials demonstrating no difference in locoregional recurrence, distant recurrence, or overall survival between SCRT and LRCCT, adaptation of SCRT in the United States has been low given concerns for less tumor downstaging and increased toxicity. In the setting of the ongoing and likely prolonged COVID-19 pandemic, we feel that these concerns must be re-evaluated, as SCRT presents a well-validated alternative that will allow us to meet the needs of a greater number of potentially curable patients, at a time when our resources are severely and acutely constrained."],"journal":"Adv Radiat Oncol","authors":["Romesser, Paul B","Wu, Abraham J","Cercek, Andrea","Smith, J Joshua","Weiser, Martin","Saltz, Leonard","Garcia-Aguilar, Julio","Crane, Christopher H"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32322758","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.adro.2020.04.011","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664895932845522944,"score":214.11505},{"pmid":32247066,"pmcid":"PMC7118621","title":"Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","text":["Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1-2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance.","J Gynecol Obstet Hum Reprod","Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril","32247066"],"abstract":["INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1-2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance."],"journal":"J Gynecol Obstet Hum Reprod","authors":["Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247066","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jogoh.2020.101729","keywords":["covid-19","guideline","gynaecological cancer","management"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["ovarian"],"_version_":1664638040194154496,"score":211.73701},{"pmid":32313873,"pmcid":"PMC7164906","title":"How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation.","text":["How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation.","The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.","Hematol Transfus Cell Ther","Perini, Guilherme Fleury","Fischer, Thais","Gaiolla, Rafael Dezen","Rocha, Talita Bueno","Bellesso, Marcelo","Teixeira, Larissa Lane Cardoso","Delamain, Marcia Torresan","Scheliga, Adriana Alves de Souza","Ribeiro, Glaciano Nogueira","Neto, Jorge Vaz","Baiocchi, Otavio Cesar Carvalho Guimaraes","Abdo, Andre Neder Ramires","Arrais-Rodrigues, Celso","Fogliatto, Laura M","Bigni, Ricardo de Sa","Schaffel, Rony","Biasoli, Irene","Pereira, Juliana","Nablan, Samir Kanaan","Souza, Carmino Antonio de","Chiattone, Carlos Sergio","32313873"],"abstract":["The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients."],"journal":"Hematol Transfus Cell Ther","authors":["Perini, Guilherme Fleury","Fischer, Thais","Gaiolla, Rafael Dezen","Rocha, Talita Bueno","Bellesso, Marcelo","Teixeira, Larissa Lane Cardoso","Delamain, Marcia Torresan","Scheliga, Adriana Alves de Souza","Ribeiro, Glaciano Nogueira","Neto, Jorge Vaz","Baiocchi, Otavio Cesar Carvalho Guimaraes","Abdo, Andre Neder Ramires","Arrais-Rodrigues, Celso","Fogliatto, Laura M","Bigni, Ricardo de Sa","Schaffel, Rony","Biasoli, Irene","Pereira, Juliana","Nablan, Samir Kanaan","Souza, Carmino Antonio de","Chiattone, Carlos Sergio"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313873","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.htct.2020.04.002","keywords":["chronic lymphocytic leukemia","covid-19","covid","coronavirus","lymphoid malignancies","lymphoma"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Brazilian"],"countries":["Brazil"],"countries_codes":["BRA|Brazil"],"_version_":1664714520034017281,"score":209.35101},{"pmid":32292839,"pmcid":"PMC7118610","title":"Prostate Cancer Radiotherapy Recommendations in Response to COVID-19.","text":["Prostate Cancer Radiotherapy Recommendations in Response to COVID-19.","Purpose: During a global pandemic the benefit of routine visits and treatment of cancer patients must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers Radiation Oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiotherapy management decisions. Patients and Methods: Radiation Oncologists from the United States and United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage prostate cancer patients during the COVID-19 pandemic. A RADS framework was created: Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy was applied to determine appropriate approaches. Results: Recommendations are provided by National Comprehensive Cancer Network (NCCN) risk group, including clinical node positive, post-prostatectomy, oligometastatic, and low volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits was deemed safe based on stage of disease between 1-6 months. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node positive, recurrence post-surgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4-6 months as necessary. Ultrahypofractionation was preferred for localized, oligometastatic, and low volume M1, and moderate hypofractionation was preferred for post-prostatectomy and clinical node positive disease. Salvage was preferred to adjuvant radiation. Conclusion: Resources can be reduced for all identified stages of prostate cancer. The RADS (Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy) framework can be applied to other disease sites to help with decision making in a global pandemic.","Adv Radiat Oncol","Zaorsky, Nicholas G","Yu, James B","McBride, Sean M","Dess, Robert T","Jackson, William C","Mahal, Brandon A","Chen, Ronald","Choudhury, Ananya","Henry, Ann","Syndikus, Isabel","Mitin, Timur","Tree, Alison","Kishan, Amar U","Spratt, Daniel E","32292839"],"abstract":["Purpose: During a global pandemic the benefit of routine visits and treatment of cancer patients must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers Radiation Oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiotherapy management decisions. Patients and Methods: Radiation Oncologists from the United States and United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage prostate cancer patients during the COVID-19 pandemic. A RADS framework was created: Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy was applied to determine appropriate approaches. Results: Recommendations are provided by National Comprehensive Cancer Network (NCCN) risk group, including clinical node positive, post-prostatectomy, oligometastatic, and low volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits was deemed safe based on stage of disease between 1-6 months. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node positive, recurrence post-surgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4-6 months as necessary. Ultrahypofractionation was preferred for localized, oligometastatic, and low volume M1, and moderate hypofractionation was preferred for post-prostatectomy and clinical node positive disease. Salvage was preferred to adjuvant radiation. Conclusion: Resources can be reduced for all identified stages of prostate cancer. The RADS (Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy) framework can be applied to other disease sites to help with decision making in a global pandemic."],"journal":"Adv Radiat Oncol","authors":["Zaorsky, Nicholas G","Yu, James B","McBride, Sean M","Dess, Robert T","Jackson, William C","Mahal, Brandon A","Chen, Ronald","Choudhury, Ananya","Henry, Ann","Syndikus, Isabel","Mitin, Timur","Tree, Alison","Kishan, Amar U","Spratt, Daniel E"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292839","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.adro.2020.03.010","keywords":["coronavirus","prostate cancer","radiation oncology","radiotherapy"],"locations":["United States","United Kingdom"],"countries":["United Kingdom","United States"],"countries_codes":["GBR|United Kingdom","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1665420446788485120,"score":203.25644}]}